ALLMedicine™ Immunofixation Center
Research & Reviews 262 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848311
Renal Failure; Zhu L, Wang L et. al.
Jan 13th, 2023 - Crystal-storing histiocytosis (CSH), light chain proximal tubulopathy (LCPT), and light chain crystalline podocytopathy (LCCP) are rare complications of multiple myeloma (MM) or monoclonal gammopathy of renal significance, and their diagnoses are ...
http://emedicine.medscape.com/article/204369-workup
Jan 13th, 2023 - Approach Considerations The International Myeloma Workshop developed guidelines for standard investigative workup in patients suspected to have multiple myeloma. These guidelines include the following: [1] Serum and urine assessment for monoclonal...
https://emedicine.medscape.com/article/204369-guidelines
Jan 13th, 2023 - Guidelines Summary Diagnosis Similar recommendations for the standard investigational workup for suspected myeloma have been issued by the following organizations: International Myeloma Working Group [135] National Comprehensive Cancer Network (NC...
https://doi.org/10.1093/ehjci/jeac249
European Heart Journal. Cardiovascular Imaging; Slivnick JA, Alvi N et. al.
Jan 10th, 2023 - While cardiac magnetic resonance (CMR) is often obtained early in the evaluation of suspected cardiac amyloidosis (CA), it currently cannot be utilized to differentiate immunoglobulin (AL) and transthyretin (ATTR) CA. We aimed to determine whether...
https://doi.org/10.1093/clinchem/hvac190
Clinical Chemistry; Hu H, Xu W et. al.
Dec 23rd, 2022 - Immunofixation electrophoresis (IFE) is important for diagnosis of plasma cell disorders (PCDs). Manual analysis of IFE images is time-consuming and potentially subjective. An artificial intelligence (AI) system for automatic and accurate IFE imag...
Guidelines 3 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136169
Nature Reviews. Nephrology; Leung N, Bridoux F et. al.
Dec 5th, 2018 - The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnosti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210231
Haematologica Minnema MC, Kimby E et. al.
Oct 21st, 2016 - Bing Neel syndrome is a rare disease manifestation of Waldenström's macroglobulinemia that results from infiltration of the central nervous system by malignant lymphoplasmacytic cells. In this guideline we describe the clinical symptoms, as well a...
https://doi.org/10.1182/blood-2010-10-299529
Blood Dimopoulos M, Kyle R et. al.
Feb 5th, 2011 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monocl...
Clinicaltrials.gov 22 results
https://clinicaltrials.gov/ct2/show/NCT03201250
Dec 23rd, 2022 - In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory multiple myeloma (MM) who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib....
https://clinicaltrials.gov/ct2/show/NCT04624906
Nov 14th, 2022 - This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with WM. Patients will require a biopsy to confirm the pathology and molecular testing for MYD88, CXCR4 and P53 mutations. A bone marrow aspiration and b...
https://clinicaltrials.gov/ct2/show/NCT03376477
Sep 14th, 2022 - This is a single institution, three- arm, randomized controlled, Phase II study examining the clinical efficacy of an allogeneic GM-CSF secreting myeloma vaccine in combination with lenalidomide (with or without Prevnar) compared to lenalidomide a...
https://clinicaltrials.gov/ct2/show/NCT03413800
Jul 22nd, 2022 - Myeloma patients in first relapse after sibling or unrelated donor allogeneic transplant willing to participate in this study will be screened for eligibility. After baseline evaluation including BM aspirate for plasma cell count, minimal residual...
https://clinicaltrials.gov/ct2/show/NCT05208086
Jul 21st, 2022 - To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients. 300 evaluable patients are required. For each of them, both spo...
News 62 results
https://www.onclive.com/view/societal-determinants-of-health-in-multiple-myeloma
Oct 11th, 2022 - Transcript: Joseph Mikhael, MD: Excellent, that's helpful. On the subject of trying to figure out why and that is obviously this first module that we're looking at, Craig I'm going to turn to you for a moment because as a scientists we think mayb...
https://www.onclive.com/view/biomarker-directed-therapy-in-multiple-myeloma-signals-the-future-of-the-field
Sep 1st, 2022 - The biology of multiple myeloma has an evolving role in guiding research efforts involving diagnostic and prognostic capabilities of available biomarkers and related molecular pathways. Myeloma cells often have genetic abnormalities, and we often ...
https://www.mdedge.com/dermatology/article/257482/dermatopathology/scattered-flesh-colored-papules-linear-array-setting
Catherine Grace P. Hobayan, BS, Madison Grinnell, MD et. al.
Aug 31st, 2022 - The Diagnosis: Scleromyxedema A punch biopsy of the upper back performed at an outside institution revealed increased histiocytes and abundant interstitial mucin confined to the papillary dermis (Figures 1 and 2), consistent with the lichen myxede.
https://www.mdedge.com/fedprac/avaho/article/256893/multiple-myeloma/agent-orange-exposure-transformation-mgus-multiple
Jyothi Dodlapati, MD, James A. Hall, DO et. al.
Aug 9th, 2022 - Multiple myeloma (MM) accounts for 1% to 2% of all cancers and slightly more than 17% of hematologic malignancies in the United States. 1 MM is characterized by the neoplastic proliferation of immunoglobulin (Ig)-producing plasma cells with ≥ 10% c.
https://www.onclive.com/view/updated-pfs-and-dor-in-ikema-a-randomized-phase-3-trial-of-isatuximab-carfilzomib-and-dexamethasone-isa-kd-vs-kd-in-relapsed-mm
Jul 8th, 2022 - Background Isatuximab, (Isa), an IgG1 monoclonal antibody targeting a specific epitope of the CD38 transmembrane glycoprotein in MM, has multiple mechanisms of action: ADCC, CDC, and ADCP Direct apoptosis Immunomodulation Inhibition of ectoen...